Phosphopeptide Binding Specificities of BRCA1 COOH-terminal (BRCT) Domains
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Protein phosphorylation by protein kinases may generate docking sites for other proteins. It thus allows the assembly of signaling complexes in response to kinase activation. Several protein domains that bind phosphoserine or phosphothreonine residues have been identified, including the 14-3-3, PIN1, FHA, KIX, WD-40 domain, and polo box (Yaffe, M. B., and Elia, A. E. (2001) Curr. Opin. Cell Biol. 13, 131-138; Elia, A. E., Cantley, L. C., and Yaffe, M. B. (2003) Science 299, 1228-1231). The BRCA1 COOH-terminal (BRCT) domains are protein modules found in many proteins that regulate DNA damage responses (Koonin, E. V., Altschul, S. F., and Bork, P. (1996) Nat. Genet. 13, 266-268). Whether BRCT domains can mediate phosphorylation-dependent interactions has not been systematically investigated. We report here that the BRCT domains also recognize phosphopeptides. Oriented peptide library analysis indicated that the BRCT domains from BRCA1, MDC1, BARD1, and DNA Ligase IV preferred distinct phosphoserine-containing peptides. In addition, the interaction between BRCA1 and the BRCT binding motif of BACH1 was required for BACH1 checkpoint activity. Furthermore, BRCT domains of the yeast DNA repair protein Rad9 could bind phosphopeptides, suggesting that the BRCT domains represent a class of ancient phosphopeptide-binding modules. Potential targets of BRCT domains were identified through data base search. Structural analysis of BRCA1 BRCT repeats also predicted conserved residues that may form the phosphopeptide-binding pocket. Thus, the BRCT repeats are a new family of phosphopeptide-binding domains in DNA damage responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The C-terminal BRCT domains of BRCA1 constitute a phospho-peptide recognition domain that binds specifically to phospho-peptides containing a pSPxF (phosphor-serine-proline-x-phenylalanine) motif (Manke et al., 2003; Rodriguez et al., 2003; Yu et al., 2003).”
From The BRCA1-Interacting Protein Abraxas Is Required for Genomic Stability and Tumor Suppression (2014) · cites this paper as Rodriguez et al., 2003
In the citing paper
“Structural and biochemical analysis of BRCA1 BRCT domains bound to optimized phosphopeptides has revealed that the phenylalanine residue in the pSPxF motif is essential for the recognition of this motif by the BRCT domains (Rodriguez et al., 2003; Shiozaki et al., 2004; Williams et al., 2004).”
From The BRCA1-Interacting Protein Abraxas Is Required for Genomic Stability and Tumor Suppression (2014) · cites this paper as Rodriguez et al., 2003
Citations
Cites
SH2 domains recognize specific phosphopeptide sequences
Zhou, S. (1993) · Cell · doi:10.1016/0092-8674(93)90404-e · Cited by 2,631
Self-citationDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Signaling Through Scaffold, Anchoring, and Adaptor Proteins
Pawson, T., & Scott, J. D. (1997) · Science · doi:10.1126/science.278.5346.2075 · Cited by 2,256
MDC1 is a mediator of the mammalian DNA damage checkpoint
Stewart, G. S., Wang, B., Bignell, C. R., Taylor, A. M. R., & Elledge, S. J. (2003) · Nature · doi:10.1038/nature01446 · Cited by 874
The BRCT Domain Is a Phospho-Protein Binding Domain
Yu, X., Chini, C. C. S., He, M., Mer, G., & Chen, J. (2003) · Science · doi:10.1126/science.1088753 · Cited by 862
Self-citationA superfamily of conserved domains in DNA damage‐ responsive cell cycle checkpoint proteins
Bork, P., Hofmann, K., Bucher, P., Neuwald, A. F., Altschul, S. F., & Koonin, E. V. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.1.9034168 · Cited by 746
Identification of a RING protein that can interact in vivo with the BRCA1 gene product
Wu, L. C., Wang, Z. W., Tsan, J. T., Spillman, M. A., Phung, A., Xu, X. L., Yang, M.-C. W., Hwang, L.-Y., Bowcock, A. M., & Baer, R. (1996) · Nature Genetics · doi:10.1038/ng1296-430 · Cited by 746
Frank, R. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00137-0 · Cited by 741
Proteomic Screen Finds pSer/pThr-Binding Domain Localizing Plk1 to Mitotic Substrates
Elia, A. E. H., Cantley, L. C., & Yaffe, M. B. (2003) · Science · doi:10.1126/science.1079079 · Cited by 684
Cantor, S. B., Bell, D. W., Ganesan, S., Kass, E. M., Drapkin, R., Grossman, S., Wahrer, D. C. R., Sgroi, D. C., Lane, W. S., Haber, D. A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00304-x · Cited by 674
Research works printed but not linked: 2
- Caldecott, 1994, Mol. Cell. Biol., 14, 68
- Weinert, 1990, Mol. Cell. Biol., 10, 6554
Cited by
Items 101–200 of 232
Functions of TopBP1 in preserving genome integrity during mitosis
Bagge, J., Oestergaard, V. H., & Lisby, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.08.009 · Cited by 40
Coster, G., Hayouka, Z., Argaman, L., Strauss, C., Friedler, A., Brandeis, M., & Goldberg, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705890200 · Cited by 51
Roles of ATM and ATR in DNA double strand breaks and replication stress
Williams, R. M., & Zhang, X. (2020) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2020.11.005 · Cited by 51
Simeonov, A. M., Yasgar, A., Jadhav, A., Lokesh, G. L.-R., Klumpp-Thomas, C. A., Michael, S., Austin, C. P., Natarajan, A., & Inglese, J. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.11.039 · Cited by 50
“Structural and biochemical studies between BRCT (the C-terminal portion of BRCA1) and phosphorylated peptides have led to the identification of a pSXXF as the binding motif on the peptide and mapped the binding site to a region at the interface of the two BRCT domains of BRCA1 [12,14,18–24].”
MethodGilmore, P. M., McCabe, N., Quinn, J. E., Kennedy, R. D., Gorski, J. J., Andrews, H. N., McWilliams, S., Carty, M., Mullan, P. B., Duprex, W. P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4080 · Cited by 52
14-3-3 Protein Signaling in Development and Growth Factor Responses
Thomas, D., Guthridge, M. A., Woodcock, J. M., & Lopez, A. F. (2005) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)67009-3 · Cited by 55
Kumar, A. T., Pant, M. C., Singh, H. S., & Khandelwal, S. (2011) · Tumor Biology · doi:10.1007/s13277-011-0253-7 · Cited by 43
“This results in reduced binding of XRCC1 by PARP, leading to the accumulation of DNA damage [43].”
BackgroundPeptide Library Approach to Uncover Phosphomimetic Inhibitors of the BRCA1 C-Terminal Domain
White, E. R., Sun, L., Ma, Z., Beckta, J. M., Danzig, B. A., Hacker, D. E., Huie, M. B., Williams, D. C., Edwards, R. A., Valerie, K. C., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb500757u · Cited by 46
CtIP, a candidate tumor susceptibility gene is a team player with luminaries
Chinnadurai, G. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.09.002 · Cited by 56
Day, M. W., Rappas, M., Ptasińska, K., Boos, D., Oliver, A. W., & Pearl, L. H. (2018) · eLife · doi:10.7554/elife.39979 · Cited by 43
“Unlike phospho-peptide binding to the more commonly occurring C-terminal tandem BRCT2 arrangements (Baldock et al., 2015; Kilkenny et al., 2008; Leung et al., 2011; Rodriguez et al., 2003; Stucki et al., 2005) where the bound peptide bridges consecutive BRCT domains, the RAD9-pS387 peptide runs perpendicular to the lo…”
Coordination of Repair, Checkpoint, and Cell Death Responses to DNA Damage
Wang, J. Y. J., & Cho, S. K. (2004) · Advances in protein chemistry · doi:10.1016/s0065-3233(04)69004-8 · Cited by 46
Bajpai, D., Banerjee, A., Pathak, S., Jain, S. K., & Singh, N. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1569-y · Cited by 46
“This results in reduced binding of XRCC1 by PARP, leading to the accumulation of DNA damage [46].”
BackgroundFactors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage
Her, J., Lee, N. S., Kim, Y., & Kim, H. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw047 · Cited by 48
Shahar, O. D., Kalousi, A., Eini, L., Fisher, B., Weiss, A., Darr, J., Mazina, O. M., Bramson, S., Kupiec, M., Eden, A., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku217 · Cited by 48
“To exclude the possibility that the effects seen for the chemical compounds analyzed were due to the GR translocation to the nucleus (31,32), we examined the HDR modulators using an assay, which is independent of the GR.”
MethodThe BRCA1-Interacting Protein Abraxas Is Required for Genomic Stability and Tumor Suppression
Castillo, A., Paul, A., Sun, B., Huang, T. H., Wang, Y., Yazinski, S. A., Tyler, J., Li, L., You, M. J., Zou, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.050 · Cited by 39
“The C-terminal BRCT domains of BRCA1 constitute a phospho-peptide recognition domain that binds specifically to phospho-peptides containing a pSPxF (phosphor-serine-proline-xphenylalanine) motif (Manke et al., 2003; Rodriguez et al., 2003; Yu et al., 2003).”
BackgroundThe application of modular protein domains in proteomics
Jadwin, J. A., Ogiue-Ikeda, M., & Machida, K. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.019 · Cited by 46
“For example, ATM kinase preferentially phosphorylates serine sites that are favored by MDC1 BRCT domains, while Chk kinase phosphorylates the motif recognized by 14-3-3 [123,124].”
BackgroundPhosphopeptide interactions with BRCA1 BRCT domains: More than just a motif
Wu, Q., Jubb, H. C., & Blundell, T. L. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.02.003 · Cited by 45
“One of the most significant properties for BRCA1 BRCT domains is their ability to bind phosphorylated proteins containing the sequence motif pSXXF (where p indicates phosphorylation) (Manke et al., 2003; Rodriguez et al., 2003; Yu et al., 2003) (Fig.”
BackgroundKumar, V., Lakshman, P. K. C., Prasad, T. K., Manjunath, K., Bairy, S. G., Vasu, A. S., Ganavi, B., Jasti, S., & Kamariah, N. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23864 · Cited by 50
DeRose, E. F., Clarkson, M. W., Gilmore, S., Galban, C. J., Tripathy, A., Havener, J. M., Mueller, G. A., Ramsden, D. A., London, R. E., & Lee, A. L. (2007) · Biochemistry · doi:10.1021/bi7007728 · Cited by 45
Wu, Y., & Brosh, R. M. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167159 · Cited by 46
Understanding Germ-Line Mutations inBRCA1
Szabo, C. I., Worley, T., & Monteiro, Á. N. A. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.6.841 · Cited by 43
Lane, T. F. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.6.843 · Cited by 50
BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis
Li, Q., & Engebrecht, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668309 · Cited by 39
“The BRCT repeats are phosphopeptide interaction modules for binding to phosphorylated proteins (Manke et al., 2003; Rodriguez et al., 2003; Yu et al., 2003).”
BackgroundhPso4/hPrp19: a critical component of DNA repair and DNA damage checkpoint complexes
Mahajan, K. N. (2015) · Oncogene · doi:10.1038/onc.2015.321 · Cited by 36
Structural basis for phosphorylation-dependent signaling in the DNA-damage response
Williams, R. S., Bernstein, N. K., Lee, M. S., Rakovszky, M. L., Cui, D., Green, R., Weinfeld, M., & Glover, J. N. M. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-153 · Cited by 38
“Indeed, a number of other BRCT-containing proteins, including PTIP, 53BP1, and BARD1, have demonstrated phosphopeptide-binding activity (Rodriguez et al. 2003; Yu et al. 2003; Manke et al. 2003).”
BackgroundKliche, J., & Ivarsson, Y. (2022) · Biochemical Journal · doi:10.1042/bcj20200714 · Cited by 39
BRCA1—A good predictive marker of drug sensitivity in breast cancer treatment?
Mullan, P. B., Gorski, J. J., & Harkin, D. P. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.07.001 · Cited by 41
The BARD1 C-Terminal Domain Structure and Interactions with Polyadenylation Factor CstF-50
Edwards, R. A., Lee, M.-S., Tsutakawa, S. E., Williams, R. S., Nazeer, I., Kleiman, F. E., Tainer, J. A., & Glover, J. N. (2008) · Biochemistry · doi:10.1021/bi801115g · Cited by 40
“In Vitro peptide binding studies suggest the BARD1 BRCT repeats may bind serinephosphorylated peptides (23), although attempts to isolate phosphorylation-dependent protein binding partners from human cells for the BARD1 BRCT region have been unsuccessful (24).”
BackgroundInfluentialChromatin and the DNA damage response
Lydall, D. A., & Whitehall, S. K. (2005) · DNA repair · doi:10.1016/j.dnarep.2005.06.007 · Cited by 37
Rtt107/Esc4 binds silent chromatin and DNA repair proteins using different BRCT motifs
Zappulla, D. C., Maharaj, A. S. R., Connelly, J. J., Jockusch, R. A., & Sternglanz, R. (2006) · BMC Molecular Biology · doi:10.1186/1471-2199-7-40 · Cited by 33
“However, not all proteins bound by BRCT motifs have the SxxF motif [61], so the precise BRCT-interacting region of Sir3 could be elsewhere.”
BackgroundOchi, T., Sibanda, B. L., Wu, Q., Chirgadze, D. Y., Bolaños-García, V. M., & Blundell, T. L. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/621695 · Cited by 46
“Indeed, in vitro phosphopeptide binding experiments showed that BRCT domains of LigIV bound phosphopeptides [96, 97].”
BackgroundAbraham, S. T., Paknikar, R., Bhumbra, S. S., Luan, D., Garg, R., Dressler, G. R., & Patel, S. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.607424 · Cited by 37
Helicase-inactivating mutations as a basis for dominant negative phenotypes
Wu, Y., & Brosh, R. M. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13667 · Cited by 32
ZNF506-dependent positive feedback loop regulates H2AX signaling after DNA damage
Nowsheen, S., Aziz, K., Luo, K., Deng, M., Qin, B., Yuan, J., Jeganathan, K. B., Yu, J., Zhang, H., Ding, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05161-0 · Cited by 33
Lokesh, G. L.-R., Rachamallu, A., Kumar, G. D. K., & Natarajan, A. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.01.025 · Cited by 36
Roles of ATM and ATR in DNA double strand breaks and replication stress
Williams, R. M., & Zhang, X. (2021) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2021.03.007 · Cited by 41
Chen, Y., Liu, H., Zhang, H., Sun, C., Hu, Z., Tian, Q., Peng, C., Jiang, P., Hua, H. M., Li, X., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1212 · Cited by 36
ACCA Phosphopeptide Recognition by the BRCT Repeats of BRCA1
Ray, H., Moreau, K., Dizin, É., Callebaut, I., & Venezia, N. D. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.04.010 · Cited by 36
Singh, N., Wiltshire, T. D., Thompson, J. R., Mer, G., & Couch, F. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.307868 · Cited by 29
“First identified as a repeating unit in BRCA1 (35–38), the tandem BRCT domains are ubiquitous and conserved motifs across phyla that recognize the phosphoserine/phosphothreonine mark on proteins with high selectivity (10, 11, 39).”
BackgroundMa, J., Dai, Q., Li, X., Zhu, X., Ma, T., Qiao, X., Shen, S., & Liu, X. (2017) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.01.057 · Cited by 30
Human DNA ligase IV is able to use NAD+ as an alternative adenylation donor for DNA ends ligation
Chen, S.-H., & Yu, X. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1202 · Cited by 33
“Originally, we and others found that a set of BRCT domain such as the BRCA1 BRCT domain is a phospho-Ser binding domain (24–26).”
Self-citationReduced repair of 8-hydroxyguanine in the human breast cancer cell line, HCC1937
Nyaga, S. G., Lohani, A., Jaruga, P., Trzeciak, A. R., Dizdaroğlu, M., & Evans, M. K. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-297 · Cited by 29
“It is noteworthy that the deleted carboxyl terminal domain of BRCA1 in HCC1937 contains the BRCT domain that is thought to mediate BRCA1 interactions with other DNA interactive proteins [48] and is also found in many other proteins involved in DNA repair and DNA damage cell cycle check point control [49-51].”
Coster, G., Gold, A., Chen, D., Schatz, D. G., & Goldberg, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.402487 · Cited by 30
“Phospho-serine peptide library binding experiments show that the tBRCT domain of MDC1 preferentially binds peptides with glutamic acid at position 2 and an aromatic residue at position 3 (24, 43).”
BackgroundActivation of DNA damage response signaling in mammalian cells by ionizing radiation
Ghosh, S., & Ghosh, A. (2021) · Free Radical Research · doi:10.1080/10715762.2021.1876853 · Cited by 33
“The C-terminus BRCT repeats of BRCA1 have been reported to bind phosphoproteins [76].”
BackgroundSjøttem, E., Rekdal, C., Svineng, G., Sagen-Johnsen, S., Klenow, H., Uglehus, R. D., & Johansen, T. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm739 · Cited by 29
Gaiser, O. J., Ball, L., Schmieder, P., Leitner, D., Strauss, H. M., Wahl, M., Kühne, R., Oschkinat, H., & Heinemann, U. (2004) · Biochemistry · doi:10.1021/bi049550q · Cited by 32
BRCA1 in breast and ovarian cancer predisposition
Billack, B., & Monteiro, Á. N. A. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.11.006 · Cited by 29
“Several independent studies have shown that the BRCT domains of BRCA1 can specifically recognize phosphoserine-containing peptides, suggesting a mechanism by which these domains recruit phosphorylated signaling factors or complexes [54–56].”
BackgroundPAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Jhuraney, A., Woods, N. T., Wright, G. M., Rix, L. L. R., Kinose, F., Kroeger, J. L., Remily-Wood, E. R., Cress, W. D., Koomen, J. M., Brantley, S. G., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0182 · Cited by 26
“org Mol Cancer Ther; 15(7) July 2016 1679 PAXIP1 Potentiates WEE1 Inhibitor Action”
InfluentialBRCA1 the Versatile Defender: Molecular to Environmental Perspectives
Zhong, A. X., Chen, Y., & Chen, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814276 · Cited by 27
Functional Evolution of BRCT Domains from Binding DNA to Protein
Sheng, Z., Zhao, Y., & Huang, J. (2011) · Evolutionary Bioinformatics · doi:10.4137/ebo.s7084 · Cited by 29
Tandem BRCT Domains: DNA's Praetorian Guard
Mesquita, R. D., Woods, N. T., Seabra-Junior, E. S., & Monteiro, Á. N. A. (2010) · Genes & Cancer · doi:10.1177/1947601910392988 · Cited by 28
Periasamy, J., Kurdekar, V., Jasti, S., Nijaguna, M. B., Boggaram, S. S., Hurakadli, M. A., Raina, D., Kurup, L. M., Chintha, C., Manjunath, K., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.02.012 · Cited by 24
Yan, J., Yang, X.-P., Kim, Y. S., & Jetten, A. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5950 · Cited by 24
“The structural integrity of the BRCT tandem repeats is essential for the interaction of BRCA1 with phosphorylated protein targets (26, 27 ).”
BackgroundStructural mechanisms underlying signaling in the cellular response to DNA double strand breaks
Mermershtain, I., & Glover, J. N. M. (2013) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2013.07.004 · Cited by 22
“BRCA1 can also exist in at least two other complexes; one with the nuclease-associated protein, CtIP [56-57], and the other with the Fanconi anemia-associated helicase, FancJ (also known as BACH1/BRIP1) [58-59].”
BackgroundDever, S. M., White, E. R., Hartman, M. C. T., & Valerie, K. C. (2012) · Cell Cycle · doi:10.4161/cc.11.4.19212 · Cited by 26
Afrin, M., Kishmiri, H., Sandhu, R. S., Rabbani, M. A. G., & Li, B. (2020) · mSphere · doi:10.1128/msphere.00027-20 · Cited by 18
“All known RAP1s also have a BRCA1 C terminus (BRCT) domain (4, 11, 12, 16) that is found in many proteins involved in DNA damage repair and replication (60, 61) and that frequently interacts with phosphorylated peptides (62–64).”
Thermal unfolding of human BRCA1 BRCT-domain variants
Nikolopoulos, G., Pyrpassopoulos, S., Thanassoulas, A., Klimentzou, P., Zikos, C. C., Vlassi, M., Vorgias, C. E., Yannoukakos, D., & Nounesis, G. (2007) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.03.018 · Cited by 21
“The structural integrity of the tandem repeats is essential for the molecule's interaction with phosphorylated protein targets [9] including the DNA helicase BACH1 and the CtBP-interacting protein CtIP [10].”
BackgroundAblation of the Brca1–Palb2 Interaction Phenocopies Fanconi Anemia in Mice
Park, D., Bergin, S. M., Jones, D. M., Ru, P., Koivisto, C. S., Jeon, Y.-J., Sizemore, G. M., Kladney, R. D., Hadjis, A. D., Shakya, R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0486 · Cited by 22
“Cancer Res; 80(19) October 1, 2020 CANCER RESEARCH 4174”
BackgroundInfluentialCell cycle regulation of the BRCA1/acetyl-CoA-carboxylase complex
Ray, H., Suau, F., Vincent, A., & Venezia, N. D. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.090 · Cited by 25
Shahar, O. D., Gabizon, R., Feine, O., Alhadeff, R., Ganoth, A., Argaman, L., Shimshoni, E., Friedler, A., & Goldberg, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078472 · Cited by 24
“[46,47,65] and therefore a subject of these interactions are”
BackgroundCheckpoint and Coordinated Cellular Responses to DNA Damage
Yang, X. H., & Zou, L. (2006) · Springer eBooks · doi:10.1007/b136684 · Cited by 29
Comparison of BRCT domains of BRCA1 and 53BP1: A biophysical analysis
Ekblad, C., Friedler, A., Veprintsev, D. B., Weinberg, R. L., & Itzhaki, L. S. (2004) · Protein Science · doi:10.1110/ps.03461404 · Cited by 19
“Most recently, the BRCT repeat was shown to recognize phosphopeptide motifs (Manke et al. 2003; Rodriguez et al. 2003; Yu et al. 2003), although interactions involving BRCT domains are thought not to be exclusively phosphorylation dependent.”
BackgroundPhospho-peptide binding domains in S. cerevisiae model organism
Panni, S. (2019) · Biochimie · doi:10.1016/j.biochi.2019.06.005 · Cited by 25
Functional Impacts of the BRCA1-mTORC2 Interaction in Breast Cancer
Krieger, K. L., Hu, W., Ripperger, T. J., & Woods, N. T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235876 · Cited by 21
“Functional and structural characterization of the BRCA1 tBRCT has revealed that it is essential for the recognition of DNA damage-induced serine phosphorylations by binding the consensus sequence phospho-SXXF (pSXXF) [16,17].”
BackgroundWu, L., Crawley, C. D., Garofalo, A., Nichols, J. W., Campbell, P.-A., Khramtsova, G. F., Olopade, O. I., Weichselbaum, R. R., & Yamini, B. (2020) · Nature Communications · doi:10.1038/s41467-020-18838-2 · Cited by 17
Key molecular DNA damage responses of human cells to radiation
Zhang, C., Liu, J., Wu, J., Ranjan, K., Cui, X., Wang, X., Zhang, D., & Zhu, S. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1422520 · Cited by 25
Ramírez-Lugo, J. S., Yoo, H. Y., Yoon, S. J., & Dunphy, W. G. (2011) · Cell Cycle · doi:10.4161/cc.10.3.14711 · Cited by 21
“BRCT repeats mainly interact with phosphorylated substrates.(31,43,44) Phosphorylation of CtIP on serine 327 (S327) of the human protein mediates the formation of a CtIP-BRCA1 complex that is involved in regulating the delay in cell cycle progression and Chk1 activation in irradiated HeLa cells.”
BackgroundCancer-associated 53BP1 mutations induce DNA damage repair defects
Zhang, J., Yan, Z., Wang, Y., Wang, Y., Guo, X., Jing, J., Dong, X., Dong, S., Liu, X., Yu, X., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.033 · Cited by 17
Self-citationRichter, S., Bergmann, R., Pietzsch, J., Ramenda, T., Steinbach, J., & Wuest, F. R. (2009) · Biopolymers · doi:10.1002/bip.21263 · Cited by 14
Thanassoulas, A., Nomikos, M., Theodoridou, M., Yannoukakos, D., Mastellos, D. C., & Nounesis, G. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.04.012 · Cited by 13
The BRCA1/BARD1 complex recognizes pre-ribosomal RNA to facilitate homologous recombination
Wu, D., Huang, H., Chen, T., Gai, X., Li, Q., Wang, C., Yao, J., Liu, Y., Cai, S., & Yu, X. (2023) · Cell Discovery · doi:10.1038/s41421-023-00590-8 · Cited by 15
Self-citationEnigmas of cardiac troponin T phosphorylation
Katrukha, I. A., & Gusev, N. B. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.09.017 · Cited by 13
Liang, S., Esswein, S. R., Ochi, T., Wu, Q., Ascher, D. B., Chirgadze, D. Y., Sibanda, B. L., & Blundell, T. L. (2016) · Structural Chemistry · doi:10.1007/s11224-016-0841-7 · Cited by 12
A new bioinformatics tool to help assess the significance of BRCA1 variants
Cusin, I., Teixeira, D., Zahn‐Zabal, M., de Laval, V. R., Gleizes, A., Viassolo, V., Chappuis, P. O., Hutter, P., Bairoch, A., & Gaudet, P. (2018) · Human Genomics · doi:10.1186/s40246-018-0168-0 · Cited by 13
“Interaction partners BRIP1 [46], RBBP8 [47 – 50], and ABRAXAS1 [51, 52] contain a consensus BRCT-interacting motif (Ser XX Phe), which is phosphorylated at Ser to mediate the interaction [53 – 55].”
BackgroundYeast two-hybrid junk sequences contain selected linear motifs
Liu, Y., Woods, N. T., Kim, D., Sweet, M., Monteiro, Á. N. A., & Karchin, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr600 · Cited by 12
Langerak, P., Krijger, P. H. L., Heideman, M. R., van den Berk, P. C. M., & Jacobs, H. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.0223 · Cited by 22
“This domain binds proteins that are phosphorylated by DNA damage-activated protein kinases ataxia telangiectasia related (ATR) and ataxia telangiectasia mutated (ATM) (Manke et al. 2003; Rodriguez et al. 2003).”
BackgroundA microchip platform for structural oncology applications
Winton, C. E., Gilmore, B. L., Demmert, A. C., Karageorge, V., Sheng, Z., & Kelly, D. F. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.16 · Cited by 11
“Although mutagenesis studies have reported that phenylalanine is the preferred residue that fits within the BRCT domain, 24,25 our modeling results suggest that the heptad repeats in the RNAP II C-terminal domain may also have binding potential for this region.”
Forma, E., Bryś, M., & Wanda, M. (2011) · InTech eBooks · doi:10.5772/22274 · Cited by 10
Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1
Pyrpassopoulos, S., Ladopoulou, A., Vlassi, M., Papanikolau, Y., Vorgias, C. E., Yannoukakos, D., & Nounesis, G. (2004) · Biophysical Chemistry · doi:10.1016/j.bpc.2004.09.014 · Cited by 16
On ubiquitin ligases and cancer
Beckmann, J. S., Maurer, F., Delorenzi, M., & Falquet, L. (2005) · Human Mutation · doi:10.1002/humu.20175 · Cited by 12
“BRCA1 has also been shown to harbor a phosphopeptide-binding BRCT domain [Meetei et al., 2003; Rodriguez et al., 2003; Yu et al., 2003].”
BackgroundThe role of BACH1 , BARD1 and TOPBP1 genes in familial breast cancer
Karppinen, S. (2009) · Cited by 11
Specificity Profiling of Protein‐Binding Domains Using One‐Bead‐One‐Compound Peptide Libraries
Kunys, A. R., Lian, W., & Pei, D. (2012) · Current Protocols in Chemical Biology · doi:10.1002/9780470559277.ch120125 · Cited by 14
“For example, SH2 domains require a pY for binding and generally two to three residues immediately N- and C-terminal to pY, respectively (Waksman et al., 1992; Songyang et al., 1993), whereas PDZ domains require a free C-terminus (Zhang et al., 1998; Manke et al., 2003; Rodriguez et al., 2003).”
BackgroundStructural mechanisms of SLF1 interactions with Histone H4 and RAD18 at the stalled replication fork
Ryder, E. L., Nasir, N., Durgan, A. E. O., Jenkyn-Bedford, M., Tye, S., Zhang, X., & Wu, Q. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae831 · Cited by 9
“:3) typically comprises a single hydrophobic residue at the +3 position relative to ‘anchor 1’ ( 76 , 82 , 83 ).”
Regulation of DNA damage response by trimeric G-proteins
El‐Hafeez, A. A. A., Sun, N. N., Chakraborty, A., Ear, J., Roy, S., Chamarthi, P., Rajapakse, N., Das, S., Luker, K. E., Hazra, T. K., et al. (2023) · iScience · doi:10.1016/j.isci.2023.105973 · Cited by 9
Effects on human transcriptome of mutated BRCA1 BRCT domain: A microarray study
Iofrida, C., Melissari, E., Mariotti, V., Guglielmi, C., Guidugli, L., Caligo, M. A., & Pellegrini, S. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-207 · Cited by 8
“BRCT repeats have been also described as phosphopeptideinteracting motifs, facilitating the assembly of DNA damage signaling complexes following checkpoint kinases activation [9].”
BackgroundBRCA/Fanconi anemia pathway genes in hereditary predisposition to breast cancer
Sólyom, S. (2011) · Cited by 7
Complex Interplay Between Obesity and BRCA1/2‐Associated Breast Cancer: An Overview
Giordano, C., Puzzo, M., Malivindi, R., Cristofaro, D., Gelsomino, L., Bonofiglio, D., Capalbo, C., Andò, S., Barone, I., & Catalano, S. (2025) · Obesity Reviews · doi:10.1111/obr.13969 · Cited by 7
Sakasai, R., Sakai, A., Iimori, M., Kiyonari, S., Matsuoka, K., Kakeji, Y., Kitao, H., & Maehara, Y. (2012) · Genes to Cells · doi:10.1111/gtc.12011 · Cited by 7
“Extensive studies have shown that phosphorylation of Ser990 on FANCJ is required for interaction with BRCA1 and that Thr1133 phosphorylation is required for interaction with TopBP1 (Rodriguez et al. 2003; Yu et al. 2003; Gong et al. 2010).”
BackgroundPre‐rRNA Facilitates TopBP1‐Mediated DNA Double‐Strand Break Response
Xin, D., Gai, X., Ma, Y., Li, Z., Li, Q., & Yu, X. (2023) · Advanced Science · doi:10.1002/advs.202206931 · Cited by 9
Self-citationIdentification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway
Guglielmi, C., Cerri, I., Evangelista, M., Collavoli, A., Tancredi, M., Aretini, P., & Caligo, M. A. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2705-9 · Cited by 6
“The BRCT repeats regulate the DNA-damage response facilitating the assembly of DNAdamage signaling complexes [9]; they also have place in the transcriptional activity of BRCA1 and they are considered the most responsible for the BRCA1 tumor suppression activity.”
BackgroundHuang, Y. M., Kang, M., & Chang, C. A. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp305028d · Cited by 9
Park, D., Gharghabi, M., Reczek, C. R., Plow, R., Yungvirt, C., Aldaz, C. M., & Huebner, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073729 · Cited by 4
“These Brca1 binding complexes are designated Brca1-BRCT A, B and C and are involved in the Brca1 repair pathway downstream functions [20,21,24,40].”
BackgroundKumar, A., Joo, W. S., Meinke, G., Moine, S., Naumova, E. N., & Bullock, P. A. (2008) · Journal of Virology · doi:10.1128/jvi.00553-08 · Cited by 4
Badgujar, D. C. (2012) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000172 · Cited by 4
“The interaction of the C-terminal domain of BRCA1 with phosphopeptide-containing protein targets is well studied [20].”
BackgroundProfiling BRCA1-BRCT interactions and their functional relevance at amino acid resolution
Mangkusaputra, V., Murachelli, A. G., Yu, Z., den Hollander, A., Menafra, R., Schreuder, A., Kloet, S. L., Sixma, T. K., & Noordermeer, S. M. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf848 · Cited by 8
“The available crystal structures of the BRCT domains binding their interactors involve only a minimal 11-or 12-amino-acid-long phospho-peptide from ABRAXAS1, BRIP1, or CtIP [ 34–39 ] including the core motif of pS-x-x-F [ 25 ].”
Preliminary crystallographic studies of BRCA1 BRCT–ABRAXAS complex
Badgujar, D. C., Sawant, U. U., Vikrant, Yadav, L. R., Hosur, M. V., & Varma, A. K. (2013) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309113030649 · Cited by 3
“The phosphopeptide-recognition sequence is pS-X1-X2-F (where pS is phosphorylated serine, X1 is an aromatic amino acid, X2 is a hydrophobic amino acid and F is phenylalanine; Yu et al., 2003; Rodriguez et al., 2003; Manke et al., 2003).”
BackgroundKinner, A., Wu, W., Staudt, C., & Iliakis, G. E. (2008) · Cited by 3
Smerdon, S. J., & Yaffe, M. B. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00072-3 · Cited by 5
A TOPBP1 allele causing male infertility uncouples XY silencing dynamics from sex body formation
Ascenção, C. F. R., Sims, J. R., Dziubek, A., Comstock, W. J., Fogarty, E. A., Badar, J., Freire, R., Grimson, A., Weiss, R. S., Cohen, P. E., et al. (2024) · eLife · doi:10.1101/2023.05.31.543071 · Cited by 10
The role of rRNA in maintaining genome stability
Li, P., & Yu, X. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103692 · Cited by 3
Self-citation
Metadata
- Authors
- Rodriguez, M., Yu, X., Chen, J., & Songyang, Z.
- Affiliations
- Baylor College of Medicine (US)
- Mayo Clinic (US)
- Corresponding author
- Songyang, Zhou
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 278
- Issue
- 52
- Pages
- 52914-52918
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2105395542
- Cited by
- 234
- References
- 40
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 12 · 2022: 2 · 2021: 4 · 2020: 8 · 2019: 4 · 2018: 7 · 2017: 4 · 2016: 7 · 2015: 10 · 2014: 3 · 2013: 11 · 2012: 15
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6144 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM569209)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- BRCA1, BRCT domain, phosphopeptide binding, protein phosphorylation, protein-protein interaction, DNA damage response, MDC1, BARD1, DNA ligase IV, BACH1, Rad9, signaling complex assembly
- MeSH terms
- DNA Ligase ATP, Carrier Proteins, DNA Damage, DNA Repair, DNA-Binding Proteins, Dose-Response Relationship, Drug, Dose-Response Relationship, Radiation, HeLa Cells, Humans, Microscopy, Fluorescence, Mitosis, Mutation, Nuclear Proteins, Peptides, Phosphorylation, Phosphoserine, DNA Ligases, Protein Binding, Transcription Factors, Signal Transduction, Trans-Activators, Gene Library, G2 Phase, Protein Structure, Tertiary, Cell Cycle Proteins, BRCA1 Protein, Genes, BRCA1, Amino Acid Motifs, Tumor Suppressor Proteins, RNA, Small Interfering, Ubiquitin-Protein Ligases, Adaptor Proteins, Signal Transducing, Basic-Leucine Zipper Transcription Factors, Fanconi Anemia Complementation Group Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.